APTEVO THERAPEUTICS INC
(NASDAQ: APVO)

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.

4.690

+0.630 (+15.52%)
Range - - -   (-%)
Open 4.050
Previous Close 4.060
Bid Price 1.670
Bid Volume 18
Ask Price 1.690
Ask Volume 8
Volume 304,555
Value -
Remark
Delayed prices. Updated at 29 Mar 2024 04:00.
Data powered by
View All Events


Loading Chart...

Please login to view stock data and analysis